Research Progress of DCLK1 Inhibitors as Cancer Therapeutics

Area of Science:

• Gastrointestinal stem cell biology
• Cancer biology
• Molecular oncology

Background:

• Doublecortin-like kinase 1 (DCLK1) is identified as a key stem cell marker in gastrointestinal tissues.
• DCLK1 expression is linked to tissue regeneration and cancer stem cell populations in mouse models.
• Specific DCLK1 isoforms are overexpressed in various cancers, presenting a therapeutic vulnerability.

Purpose of the Study:

• To review the evidence supporting Doublecortin-like kinase 1 (DCLK1) as a potential cancer therapeutic target.
• To examine the isoform-specific expression and mutational landscape of DCLK1 in human cancers.
• To discuss the progress and challenges in developing small molecule inhibitors against DCLK1.

Main Methods:

• Literature review of studies on DCLK1 in gastrointestinal tissues and cancer.
• Analysis of DCLK1 isoform expression patterns in normal versus cancerous human tissues.
• Examination of DCLK1 mutational status across different cancer types.
• Review of current small molecule inhibitor development for DCLK1.

Main Results:

• DCLK1 marks stem cells involved in tissue regeneration and cancer stem cell activity.
• Aberrant expression of specific DCLK1 isoforms is a hallmark of many human cancers.
• DCLK1 presents a targetable vulnerability due to its differential expression in cancer cells.

Conclusions:

• DCLK1 is a compelling target for cancer therapy due to its role in stemness and cancer-specific expression.
• Targeting DCLK1 kinase activity or expression holds potential for inhibiting cancer progression.
• Development of DCLK1 inhibitors is advancing, though challenges remain in clinical translation.